Summit Therapeutics COO/CFO Buys $722K in Shares After Positive Drug Data
SMMT is trading near its 52-week low of $13.83 (7.2% above the low).
Summary
Summit Therapeutics' COO and CFO, Manmeet Soni, purchased $722,250 worth of company stock on the open market, following recent positive Phase III clinical trial results for ivonescimab.
Key Events · Ownership and Investor Activity · SMMT
-
Executive Stock Purchase
COO and CFO Manmeet Soni acquired 50,000 shares of Summit Therapeutics common stock for a total of $722,250 in open market transactions.
-
Reinforces Confidence
This open market purchase by a key executive signals strong internal conviction following the recent positive Phase III clinical trial results for ivonescimab.
-
Follows Buying Intent
The transaction occurs shortly after an 8-K filing where executives and affiliates expressed intent to purchase shares, indicating a planned show of confidence.
Analysis · SMMT · Life Sciences
This significant open market purchase by a top executive reinforces confidence in Summit Therapeutics, especially coming just days after the company announced groundbreaking Phase III data for its lead drug candidate, ivonescimab. It also follows a recent 8-K where executives expressed intent to buy shares, indicating strong internal conviction in the company's prospects after the clinical success.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1838 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMMT was trading at $14.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $13.83 to $30.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.